The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes

Author： Nelson Robert H   Miles John M  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.14, 2005-11, pp. : 2483-2491

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Orlistat: In the Prevention and Treatment of Type 2 Diabetes Mellitus

By Keating G.M.   Jarvis B.  

Drugs, Vol. 61, Iss. 14, 2001-01 ,pp. : 2107-2119

Adis International

Access to resources Recommend Favorite

Orlistat in the treatment of Type 2 diabetes mellitus

By Jneidi Muna   Kelley David E  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 599-605

Informa Healthcare

Access to resources Recommend Favorite

Orlistat gains merit in type 2 diabetes mellitus

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 413, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Orlistat in the treatment of obesity

By Ballinger A.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 841-847

Informa Healthcare

Access to resources Recommend Favorite

Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus

By Keating Gillian M.   Croom Katherine F.  

Drugs, Vol. 67, Iss. 1, 2007-01 ,pp. : 121-153

Adis International

Access to resources Recommend Favorite